| Biomarker ID | 1140 |
| PMID | 23781281 |
| Year | 2013 |
| Biomarker | hsa-miR-10b; hsa-miR-15a; hsa-miR-15b; hsa-miR-16; hsa-miR-18a; hsa-miR-18b; hsa-miR-25; hsa-miR-30c; hsa-miR-32; hsa-miR-34a; hsa-miR-34c-5p; hsa-miR-92a; hsa-miR-181a; hsa-miR-181b; hsa-miR-181c; hsa-miR-184; hsa-miR-122; hsa-miR-124; hsa-miR-125a-5p; hsa-miR-125b; hsa-miR-128a; hsa-miR-133b; hsa-miR-134; hsa-miR-135b; hsa-miR-146b-5p; hsa-miR-148b; hsa-miR-193a-5p; hsa-miR-193b hsa-miR-206; hsa-miR-20b; hsa-miR-214; hsa-miR-215; hsa-miR-301a; hsa-miR-372 |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated with fold change > 2 |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | prostate tumor Vs normal epithelium |
| Type of Biomarker | Diagnostic |
| Cohort | 40 patients with prostate cancer and 10 normal epithelium were taken in the study |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | RT-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |